Melatonin for Atypical Antipsychotic-Induced Metabolic Adverse Effects

A Meta-Analysis of Randomized Controlled Trials

Ashwin Kamath, Zahoor Ahmad Rather

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The objective of our study was to determine the effect of melatonin administration on atypical antipsychotic-induced metabolic adverse effects in patients with psychiatric disorders. A systematic search was performed in PUBMED, Cochrane Library, Scopus, Web of Science, and EBSCOhost electronic databases. Randomized controlled trials studying the effect of melatonin on antipsychotic-induced metabolic adverse effects were identified and subjected to meta-analysis. Four studies were included in the meta-analysis, including 57 patients on melatonin and 61 patients on placebo. Melatonin produced a significant decrease in the diastolic blood pressure compared with placebo (mean difference = -4.44 [95% CI, -7.00 to -1.88]; p=0.0007; I2 = 13%), but not the systolic blood pressure (mean difference = -4.23 [95% CI, -8.11 to -0.36]; p=0.03; I2 = 0%). Although a decrease in the body mass index was seen in the melatonin group, the difference was not significant in the random-effects analysis model. To conclude, in patients on atypical antipsychotics, melatonin at a dose of up to 5 mg/day for a treatment duration of up to 12 weeks attenuated the rise in diastolic blood pressure compared with placebo but had no significant effects on other metabolic parameters.

Original languageEnglish
Article number4907264
JournalBioMed Research International
Volume2018
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Melatonin
Antipsychotic Agents
Meta-Analysis
Randomized Controlled Trials
Blood Pressure
Blood pressure
Placebos
Libraries
Psychiatry
Body Mass Index
Databases

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

@article{9a280e5d680f4b1bac71ae010b9184fd,
title = "Melatonin for Atypical Antipsychotic-Induced Metabolic Adverse Effects: A Meta-Analysis of Randomized Controlled Trials",
abstract = "The objective of our study was to determine the effect of melatonin administration on atypical antipsychotic-induced metabolic adverse effects in patients with psychiatric disorders. A systematic search was performed in PUBMED, Cochrane Library, Scopus, Web of Science, and EBSCOhost electronic databases. Randomized controlled trials studying the effect of melatonin on antipsychotic-induced metabolic adverse effects were identified and subjected to meta-analysis. Four studies were included in the meta-analysis, including 57 patients on melatonin and 61 patients on placebo. Melatonin produced a significant decrease in the diastolic blood pressure compared with placebo (mean difference = -4.44 [95{\%} CI, -7.00 to -1.88]; p=0.0007; I2 = 13{\%}), but not the systolic blood pressure (mean difference = -4.23 [95{\%} CI, -8.11 to -0.36]; p=0.03; I2 = 0{\%}). Although a decrease in the body mass index was seen in the melatonin group, the difference was not significant in the random-effects analysis model. To conclude, in patients on atypical antipsychotics, melatonin at a dose of up to 5 mg/day for a treatment duration of up to 12 weeks attenuated the rise in diastolic blood pressure compared with placebo but had no significant effects on other metabolic parameters.",
author = "Ashwin Kamath and Rather, {Zahoor Ahmad}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/4907264",
language = "English",
volume = "2018",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Melatonin for Atypical Antipsychotic-Induced Metabolic Adverse Effects : A Meta-Analysis of Randomized Controlled Trials. / Kamath, Ashwin; Rather, Zahoor Ahmad.

In: BioMed Research International, Vol. 2018, 4907264, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Melatonin for Atypical Antipsychotic-Induced Metabolic Adverse Effects

T2 - A Meta-Analysis of Randomized Controlled Trials

AU - Kamath, Ashwin

AU - Rather, Zahoor Ahmad

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The objective of our study was to determine the effect of melatonin administration on atypical antipsychotic-induced metabolic adverse effects in patients with psychiatric disorders. A systematic search was performed in PUBMED, Cochrane Library, Scopus, Web of Science, and EBSCOhost electronic databases. Randomized controlled trials studying the effect of melatonin on antipsychotic-induced metabolic adverse effects were identified and subjected to meta-analysis. Four studies were included in the meta-analysis, including 57 patients on melatonin and 61 patients on placebo. Melatonin produced a significant decrease in the diastolic blood pressure compared with placebo (mean difference = -4.44 [95% CI, -7.00 to -1.88]; p=0.0007; I2 = 13%), but not the systolic blood pressure (mean difference = -4.23 [95% CI, -8.11 to -0.36]; p=0.03; I2 = 0%). Although a decrease in the body mass index was seen in the melatonin group, the difference was not significant in the random-effects analysis model. To conclude, in patients on atypical antipsychotics, melatonin at a dose of up to 5 mg/day for a treatment duration of up to 12 weeks attenuated the rise in diastolic blood pressure compared with placebo but had no significant effects on other metabolic parameters.

AB - The objective of our study was to determine the effect of melatonin administration on atypical antipsychotic-induced metabolic adverse effects in patients with psychiatric disorders. A systematic search was performed in PUBMED, Cochrane Library, Scopus, Web of Science, and EBSCOhost electronic databases. Randomized controlled trials studying the effect of melatonin on antipsychotic-induced metabolic adverse effects were identified and subjected to meta-analysis. Four studies were included in the meta-analysis, including 57 patients on melatonin and 61 patients on placebo. Melatonin produced a significant decrease in the diastolic blood pressure compared with placebo (mean difference = -4.44 [95% CI, -7.00 to -1.88]; p=0.0007; I2 = 13%), but not the systolic blood pressure (mean difference = -4.23 [95% CI, -8.11 to -0.36]; p=0.03; I2 = 0%). Although a decrease in the body mass index was seen in the melatonin group, the difference was not significant in the random-effects analysis model. To conclude, in patients on atypical antipsychotics, melatonin at a dose of up to 5 mg/day for a treatment duration of up to 12 weeks attenuated the rise in diastolic blood pressure compared with placebo but had no significant effects on other metabolic parameters.

UR - http://www.scopus.com/inward/record.url?scp=85043364913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043364913&partnerID=8YFLogxK

U2 - 10.1155/2018/4907264

DO - 10.1155/2018/4907264

M3 - Article

VL - 2018

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 4907264

ER -